ACTG

Acacia Research Corp. 10-Q Summary: Period Ended September 30, 2002

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2002. Acacia Research Corporation operates in two primary segments: the Acacia Media Technologies Group, which licenses intellectual property related to telecommunications (including the V-chip and digital media transmission), and the Acacia Life Sciences Group, centered on its subsidiary CombiMatrix Corporation, which develops biochip array processor systems for genomic and proteomic research. As of November 12, 2002, the company had 19,640,808 shares of common stock outstanding.

Key Financial Metrics

Note: Working capital calculated as Total Current Assets ($62,067) minus Total Current Liabilities ($22,498).

Material Changes vs. Prior Period

• Revenue Collapse: Total revenues plummeted from $23.5 million in the nine months of 2001 to $0.9 million in the same period of 2002. This is primarily due to a drop in license fee income from $23.2 million to $43,000, as the company executed only one new license agreement (Loewe Opta GmbH) in 2002 compared to multiple settlements in 2001.
• Legal Settlement Charge: A significant non-cash charge of $18.5 million was recorded in the third quarter of 2002 related to a settlement with Nanogen, Inc. This included $17.5 million for the fair value of CombiMatrix shares issued to Nanogen and $1.0 million in accrued cash payments.
• Investment Impairment: The company recorded a $2.7 million impairment charge for an other-than-temporary decline in the fair value of a cost method investment.
• Operating Expenses: While total operating expenses decreased slightly year-over-year for the nine-month period ($54.4M vs $57.0M), this was largely due to a reduction in stock-based compensation and legal fees related to prior settlements, offset by increased R&D spending for CombiMatrix.

Guidance, Outlook, and Risks

• Recapitalization Proposal: The Board approved a proposal to split the company's common stock into two classes: "AR-CombiMatrix stock" and "AR-Acacia Technologies stock." A special meeting is scheduled for December 11, 2002, to vote on this recapitalization and a merger to acquire remaining interests in CombiMatrix.
• Litigation Risks:
  • Soundview Technologies (V-Chip): A federal court granted summary judgment against Soundview in September 2002, ruling that defendants did not infringe on its V-chip patent. Acacia intends to appeal; failure to succeed could preclude future infringement claims and severely impact future revenues, especially as the patent expires in July 2003.
  • CombiMatrix (Nanogen): Litigation was settled in September 2002, but the settlement requires ongoing royalty payments (12.5% of sales up to $1.5M annually) and dilution of Acacia's ownership in CombiMatrix from 58% to 48%.
• Liquidity: The company reported $57.8 million in cash and short-term investments. Management anticipates existing reserves will fund operations for at least the next twelve months, though CombiMatrix recently paid off a $2.1 million capital lease obligation to resolve a covenant non-compliance.
• Outlook: The company expects to continue incurring significant losses due to high R&D and administrative costs. Future profitability depends on the commercialization of CombiMatrix's biochip technology and the successful licensing of new digital media technologies to replace expiring V-chip revenues.

Investor Verification Checklist

• Appeal Status: Verify the progress and likelihood of success regarding the appeal of the summary judgment ruling against Soundview Technologies' V-chip patent.
• Recapitalization Approval: Confirm the outcome of the December 11, 2002, shareholder vote on the stock split and CombiMatrix merger.
• CombiMatrix Commercialization: Assess the timeline and milestones for CombiMatrix's product commercialization, particularly its agreements with Roche and government grants.
• Patent Expiration: Review the strategy for replacing V-chip revenue streams following the July 2003 patent expiration.
• Stock-Based Compensation: Monitor the remaining deferred stock compensation balance ($5.6 million) and its impact on future earnings.